This notorious phase III, placebo-controlled, randomized trial tested the monoclonal antibody anti-IL-1β canakinumab at the dosage of 50 mg, 150 mg and 300 mg every 3 months in subjects with previous myocardial infarction and baseline levels of high-sensitive C reactive protein (hs-CRP) ≥ 2 mg/L. The gene discussed is IL1B; the disease is myocardial infarction.